
News|Articles|December 1, 2006
Telbivudine
Telbivudine was approved on October 25, 2006, for the treatment of chronic hepatitis B virus (HBV) in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
2
Healthcare’s workforce has a scale problem, but new model is emerging
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
4
Early data show vaccine has potential to prevent Lynch-related cancers | ASCO 2026
5

























